or Try an Advanced Search...

    Technical Analysis for IPHA - Innate Pharma S.A.

    Grade Last Price % Change Price Change
    D 2.51 -5.06% -0.13
    IPHA closed down 5.06 percent on Wednesday, May 15, 2024, on 88 percent of normal volume. It was able to find support at its 50 day moving average. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Flat Down
    Historical IPHA trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 0.00%
    20 DMA Support Bullish 0.00%
    50 DMA Support Bullish 0.00%
    Earnings Movers Other 0.00%
    Outside Day Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    50 DMA Support Bullish -5.06%
    Crossed Above 200 DMA Bullish -5.06%
    Pocket Pivot Bullish Swing Setup -5.06%
    Stochastic Reached Overbought Strength -5.06%
    Older End-of-Day Signals for IPHA ...

       Recent Intraday Alerts

    Alert Time
    Fell Below 50 DMA about 9 hours ago
    Fell Below 20 DMA about 9 hours ago
    Down 1 ATR about 9 hours ago
    Rose Above Previous Day's High about 10 hours ago
    Outside Day about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IPHA Chart by TradingView
    Basic chart:

    Profile

    Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity

    Is IPHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
    May 14 Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript
    May 14 Innate Pharma reports Q1 results
    May 14 Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
    May 7 Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
    Apr 15 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
    Apr 15 Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    Apr 10 All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
    Apr 10 Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
    Apr 9 Innate Pharma Announces Its Participation in Upcoming Investor Conference
    See more IPHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.57
    52 Week Low 1.81
    Average Volume 10,062
    200-Day Moving Average 2.61
    50-Day Moving Average 2.51
    20-Day Moving Average 2.48
    10-Day Moving Average 2.55
    Average True Range 0.15
    RSI (14) 49.75
    ADX 19.85
    +DI 20.96
    -DI 16.69
    Chandelier Exit (Long, 3 ATRs) 2.19
    Chandelier Exit (Short, 3 ATRs) 2.71
    Upper Bollinger Bands 2.66
    Lower Bollinger Band 2.31
    Percent B (%b) 0.56
    BandWidth 14.27
    MACD Line 0.02
    MACD Signal Line 0.01
    MACD Histogram 0.0131
    Fundamentals Value
    Market Cap 202.61 Million
    Num Shares 80.8 Million
    EPS -0.85
    Price-to-Earnings (P/E) Ratio -2.95
    Price-to-Sales 3.87
    Price-to-Book 3.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.84
    Resistance 3 (R3) 2.85 2.75 2.78
    Resistance 2 (R2) 2.75 2.66 2.74 2.76
    Resistance 1 (R1) 2.63 2.61 2.58 2.62 2.74
    Pivot Point 2.53 2.53 2.50 2.52 2.53
    Support 1 (S1) 2.41 2.44 2.36 2.40 2.27
    Support 2 (S2) 2.31 2.39 2.30 2.25
    Support 3 (S3) 2.19 2.31 2.23
    Support 4 (S4) 2.18